Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.
You may also be interested in...
Cell Genesys’ New Data Bolster GVAX Survival Mechanism
Phase II antibody responses – two, so far – help “peel the onion,” chief financial officer tells “The Pink Sheet” DAILY.
Cell Genesys’ New Data Bolster GVAX Survival Mechanism
Phase II antibody responses – two, so far – help “peel the onion,” chief financial officer tells “The Pink Sheet” DAILY.
Antigenics’ Oncophage Cancer Vaccine Enters Phase II Glioma Study
Brain cancer trial co-sponsored by NCI follows Phase I/II investigator-sponsored study in which a tumor-specific immune response was detected in all 12 patients.